Evan A. Stein

31.0k total citations · 15 hit papers
224 papers, 22.6k citations indexed

About

Evan A. Stein is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Cancer Research. According to data from OpenAlex, Evan A. Stein has authored 224 papers receiving a total of 22.6k indexed citations (citations by other indexed papers that have themselves been cited), including 186 papers in Surgery, 74 papers in Endocrinology, Diabetes and Metabolism and 52 papers in Cancer Research. Recurrent topics in Evan A. Stein's work include Lipoproteins and Cardiovascular Health (182 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (64 papers) and Cancer, Lipids, and Metabolism (49 papers). Evan A. Stein is often cited by papers focused on Lipoproteins and Cardiovascular Health (182 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (64 papers) and Cancer, Lipids, and Metabolism (49 papers). Evan A. Stein collaborates with scholars based in United States, South Africa and Canada. Evan A. Stein's co-authors include Antonio M. Gotto, Frederick J. Raal, Deborah R. Shapiro, Stephen E. Weis, John R. Downs, Edwin J. Whitney, Alexandra Langendörfer, Michael Clearfield, Polly A. Beere and William B. Kruyer and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Evan A. Stein

219 papers receiving 21.5k citations

Hit Papers

Primary Prevention of Acu... 1988 2026 2000 2013 1998 2003 2003 2015 2003 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels
    1998 4.1k citations Evan A. Stein et al. profile →
  2. Estrogen plus Progestin and the Risk of Coronary Heart Disease
    2003 1.4k citations Judith Hsia, Evan A. Stein et al. New England Journal of Medicine profile →
  3. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)
    2003 1.1k citations Evan A. Stein, Harold Bays et al. The American Journal of Cardiology profile →
  4. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
    2015 1.1k citations Marc S. Sabatine, Robert P. Giugliano et al. New England Journal of Medicine profile →
  5. Implementation of the women's health initiative study design
    2003 597 citations Evan A. Stein et al. profile →
  6. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
    2014 562 citations Frederick J. Raal, Evan A. Stein et al. profile →
  7. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
    2014 553 citations Frederick J. Raal, Dirk Blom et al. profile →
  8. Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol
    2012 505 citations Evan A. Stein, Scott Mellis et al. New England Journal of Medicine profile →
  9. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial
    2012 463 citations Evan A. Stein, Jean Bergeron et al. profile →
  10. THE RELATION OF DIET, CIGARETTE SMOKING, AND ALCOHOL CONSUMPTION TO PLASMA BETA-CAROTENE AND ALPHA-TOCOPHEROL LEVELS
    1988 456 citations Evan A. Stein et al. profile →
  11. Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy
    2012 416 citations James M. McKenney, Michael J. Koren et al. Journal of the American College of Cardiology profile →
  12. Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
    2012 403 citations Frederick J. Raal, Robert C. Scott et al. Circulation profile →
  13. Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia
    2012 383 citations Eli M. Roth, James M. McKenney et al. New England Journal of Medicine profile →
  14. Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
    2012 369 citations Robert C. Scott, Scott M. Wasserman et al. profile →
  15. Reduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
    2014 281 citations Frederick J. Raal, Robert P. Giugliano et al. Journal of the American College of Cardiology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Evan A. Stein 15.5k 7.2k 4.9k 3.9k 3.6k 224 22.6k
Michael H. Davidson 12.9k 0.8× 8.4k 1.2× 3.1k 0.6× 4.5k 1.1× 3.3k 0.9× 420 23.1k
Jennifer G. Robinson 14.3k 0.9× 6.2k 0.9× 6.0k 1.2× 6.0k 1.5× 2.3k 0.6× 238 24.5k
Anthony Keech 14.3k 0.9× 7.3k 1.0× 4.7k 1.0× 6.6k 1.7× 2.9k 0.8× 298 23.8k
Anders Olsson 14.9k 1.0× 7.6k 1.1× 4.2k 0.9× 6.1k 1.6× 3.0k 0.8× 301 23.6k
Kausik K. Ray 14.7k 0.9× 10.2k 1.4× 3.4k 0.7× 6.7k 1.7× 3.2k 0.9× 466 26.5k
Ole Færgeman 9.9k 0.6× 5.6k 0.8× 2.8k 0.6× 5.1k 1.3× 2.3k 0.6× 191 16.3k
Terje R. Pedersen 16.7k 1.1× 7.9k 1.1× 5.5k 1.1× 8.2k 2.1× 3.2k 0.9× 171 25.2k
James Shepherd 19.9k 1.3× 11.0k 1.5× 5.8k 1.2× 8.3k 2.1× 4.2k 1.2× 175 33.0k
James M. McKenney 10.2k 0.7× 7.6k 1.1× 3.3k 0.7× 5.0k 1.3× 2.1k 0.6× 155 21.1k
Alberico L. Catapano 14.8k 1.0× 8.4k 1.2× 3.4k 0.7× 7.3k 1.8× 4.4k 1.2× 656 30.1k

Countries citing papers authored by Evan A. Stein

Since Specialization
Citations

This map shows the geographic impact of Evan A. Stein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan A. Stein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan A. Stein more than expected).

Fields of papers citing papers by Evan A. Stein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan A. Stein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan A. Stein. The network helps show where Evan A. Stein may publish in the future.

Co-authorship network of co-authors of Evan A. Stein

This figure shows the co-authorship network connecting the top 25 collaborators of Evan A. Stein. A scholar is included among the top collaborators of Evan A. Stein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan A. Stein. Evan A. Stein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Raal, Frederick J., Vimal Mehta, Meral Kayıkçıoğlu, et al.. (2025). Lerodalcibep and evolocumab for the treatment of homozygous familial hypercholesterolaemia with PCSK9 inhibition (LIBerate-HoFH): a phase 3, randomised, open-label, crossover, non-inferiority trial. The Lancet Diabetes & Endocrinology. 13(3). 178–187. 6 indexed citations
2.
Burgess, Lesley, et al.. (2024). Long term efficacy and safety of lerodalcibep in patients with atherosclerotic cardiovascular disease (liberate-CVD). Atherosclerosis. 395. 118513–118513. 2 indexed citations
3.
Giugliano, Robert P., Marc S. Sabatine, Frederick J. Raal, et al.. (2022). Time-averaged low-density lipoprotein cholesterol lowering with evolocumab: Pooled analysis of phase 2 trials. Journal of clinical lipidology. 16(4). 538–543. 6 indexed citations
4.
Stein, Evan A., Traci Turner, Dean J. Kereiakes, et al.. (2020). EFFICACY AND SAFETY OF A 52 WEEK OPEN LABEL PHASE 2B EXTENSION TRIAL WITH MONTHLY DOSING OF AN ANTI-PCSK9 SMALL BINDING PROTEIN. Journal of the American College of Cardiology. 75(11). 2077–2077. 2 indexed citations
5.
Stein, Evan A., et al.. (2019). Abstract 17222: Safety, Tolerability and LDL-C Reduction With LIB003 a Novel Anti-PCSK9 Recombinant Fusion Protein: Results of Open-Label Extension Phase 2B Study. Circulation. 10 indexed citations
6.
Martin, Seth S., Robert P. Giugliano, Sabina A. Murphy, et al.. (2018). Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation. JAMA Cardiology. 3(8). 749–749. 99 indexed citations
7.
Stein, Evan A., Eldad J. Dann, Albert Wiegman, et al.. (2017). Efficacy of Rosuvastatin in Children With Homozygous Familial Hypercholesterolemia and Association With Underlying Genetic Mutations. Journal of the American College of Cardiology. 70(9). 1162–1170. 36 indexed citations
8.
Sabatine, Marc S., Robert P. Giugliano, Stephen D. Wiviott, et al.. (2015). Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. New England Journal of Medicine. 372(16). 1500–1509. 1091 indexed citations breakdown →
9.
Gaudet, Daniel, Dean J. Kereiakes, James M. McKenney, et al.. (2014). Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials). The American Journal of Cardiology. 114(5). 711–715. 167 indexed citations
10.
Stein, Evan A., Jean Bergeron, Daniel Gaudet, et al.. (2014). ONE YEAR OPEN-LABEL TREATMENT WITH ALIROCUMAB 150 MG EVERY TWO WEEKS IN HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIC PATIENTS. Journal of the American College of Cardiology. 63(12). A1371–A1371. 5 indexed citations
11.
Stein, Evan A., Scott Mellis, George D. Yancopoulos, et al.. (2012). Effect of a Monoclonal Antibody to PCSK9 on LDL Cholesterol. Obstetrical & Gynecological Survey. 67(7). 413–414. 10 indexed citations
12.
Gaudet, Daniel, Dean J. Kereiakes, Eli M. Roth, et al.. (2012). Abstract 14725: Effect of SAR236553/REGN727 Fully Human Monoclonal Anti-Proprotein Convertase Subtilisin/Kexin Type 9 Antibody on Plasma Lipoprotein(a) Concentrations: Pooled Analysis from Three Phase 2 Studies (NCT:01266876; 01288469; 01288443). Circulation. 126. 2 indexed citations
13.
Roth, Eli M., James McKenney, Corinne Hanotin, Gaëlle Asset, & Evan A. Stein. (2012). THE EFFECTS OF CO-ADMINISTERING A MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 SERINE PROTEASE, REGN727/SAR236553, WITH 10 AND 80 MG ATORVASTATIN COMPARED TO 80 MG ATORVASTATIN ALONE IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA (NCT: 01288469). Journal of the American College of Cardiology. 59(13). E1620–E1620. 1 indexed citations
14.
Swergold, Gary D., W. Smith, Scott Mellis, et al.. (2011). Abstract 16265: Inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 With a Monoclonal Antibody REGN727/SAR236553, Effectively Reduces Low-Density-Lipoprotein Cholesterol, as Mono or Add-on Therapy in Heterozygous Familial and Non Familial Hypercholesterolemia. Circulation. 124. 6 indexed citations
15.
Avis, Hans J., Barbara A. Hutten, Claude Gagné, et al.. (2010). Efficacy and Safety of Rosuvastatin Therapy for Children With Familial Hypercholesterolemia. Journal of the American College of Cardiology. 55(11). 1121–1126. 116 indexed citations
16.
Ballantyne, Christie M., Michael R. Miller, Eric J. Niesor, et al.. (2010). EFFECT OF DALCETRAPIB PLUS PRAVASTATIN ON LIPOPROTEIN METABOLISM IN DYSLIPIDEMIC PATIENTS: RESULTS OF A PHASE 2B DOSE-RANGING STUDY. Journal of the American College of Cardiology. 55(10). A47.E444–A47.E444. 1 indexed citations
17.
Stein, Evan A.. (2009). Low-Density Lipoprotein Cholesterol Reduction and Prevention of Cardiovascular Disease. Mayo Clinic Proceedings. 84(4). 307–309. 1 indexed citations
18.
Kastelein, John J.P., Fatima Akdim, E.S.G. Stroes, et al.. (2008). Simvastatin with or without ezetimibe in familial hypercholesterolemia (vol 358, pg 1431, 2008). New England Journal of Medicine. 358(18). 10 indexed citations
19.
Bays, Harold, James McKenney, Ralph T. Doyle, Roderick N. Carter, & Evan A. Stein. (2008). Abstract 5150: Effect of Prescription Omega-3 Fatty Acids Coadministered with Escalating Doses of Atorvastatin in Patients with Hypertriglyceridemia. Circulation. 118. 3 indexed citations
20.
Bays, Harold & Evan A. Stein. (2003). Pharmacotherapy for dyslipidaemia – current therapies and future agents. Expert Opinion on Pharmacotherapy. 4(11). 1901–1938. 135 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michael H. Davidson Breakdown of academic impact, for papers by Jennifer G. Robinson Breakdown of academic impact, for papers by Anthony Keech Breakdown of academic impact, for papers by Anders Olsson Breakdown of academic impact, for papers by Kausik K. Ray Breakdown of academic impact, for papers by Ole Færgeman Breakdown of academic impact, for papers by Terje R. Pedersen Breakdown of academic impact, for papers by James Shepherd Breakdown of academic impact, for papers by James M. McKenney Breakdown of academic impact, for papers by Alberico L. Catapano
Rankless by CCL
2026